Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
Eli Lilly announced significant results from the SUMMIT Phase 3 trial of tirzepatide for heart failure with preserved ejection fraction (HFpEF) and obesity. The drug demonstrated a 38% reduction in heart failure events risk and 56% reduction in hospitalization risk compared to placebo. Patients showed improved heart failure symptoms, with a 25-point improvement in the KCCQ-CSS score versus 15 points for placebo. Key secondary endpoints revealed patients achieved 15.7% average weight loss and walked approximately 30 meters farther in six minutes than the placebo group. The drug also reduced systemic inflammation marker hsCRP by 43.4%. Lilly has initiated regulatory submissions globally.
Eli Lilly ha annunciato risultati significativi dal trial di Fase 3 SUMMIT relativo a tirzepatide per l'insufficienza cardiaca con frazione di eiezione preservata (HFpEF) e obesità. Il farmaco ha mostrato una riduzione del 38% nel rischio di eventi di insufficienza cardiaca e una riduzione del 56% nel rischio di ospedalizzazione rispetto al placebo. I pazienti hanno mostrato un miglioramento dei sintomi di insufficienza cardiaca, con un miglioramento di 25 punti nel punteggio KCCQ-CSS rispetto a 15 punti per il gruppo placebo. I principali endpoint secondari hanno rivelato che i pazienti hanno raggiunto una perdita di peso media del 15,7% e hanno camminato circa 30 metri in più in sei minuti rispetto al gruppo placebo. Il farmaco ha anche ridotto il marcatore di infiammazione sistemica hsCRP del 43,4%. Lilly ha avviato le procedure di autorizzazione a livello globale.
Eli Lilly anunció resultados significativos del ensayo de Fase 3 SUMMIT sobre tirzepatide para la insuficiencia cardiaca con fracción de eyección preservada (HFpEF) y obesidad. El fármaco demostró una reducción del 38% en el riesgo de eventos de insuficiencia cardiaca y una reducción del 56% en el riesgo de hospitalización en comparación con el placebo. Los pacientes mostraron una mejoría en los síntomas de insuficiencia cardiaca, con una mejoría de 25 puntos en la puntuación KCCQ-CSS frente a 15 puntos para el grupo placebo. Los principales objetivos secundarios revelaron que los pacientes lograron una pérdida de peso promedio del 15,7% y caminaron aproximadamente 30 metros más en seis minutos que el grupo placebo. El fármaco también redujo el marcador de inflamación sistémica hsCRP en un 43,4%. Lilly ha iniciado las solicitudes regulatorias a nivel global.
엘리 릴리는 티르제파타이드의 보존 분출 분획 심부전(HFpEF) 및 비만에 대한 SUMMIT 3상 시험에서 중요한 결과를 발표했습니다. 이 약물은 위약에 비해 심부전 사건의 위험을 38% 감소시키고 입원 위험을 56% 줄였습니다. 환자들은 심부전 증상이 개선되었으며, KCCQ-CSS 점수에서 위약에 비해 15점보다 25점 개선되었습니다. 주요 2차 목표에서는 환자들이 평균 15.7%의 체중 감소를 달성하고, 6분 동안 위약 그룹보다 약 30미터 더 걸었습니다. 이 약물은 또한 전신 염증 마커 hsCRP를 43.4% 감소시켰습니다. 릴리는 전 세계적으로 규제 제출을 시작했습니다.
Eli Lilly a annoncé des résultats significatifs de l'essai de phase 3 SUMMIT du tirzepatide pour l'insuffisance cardiaque avec fraction d'éjection préservée (HFpEF) et l'obésité. Le médicament a montré une réduction de 38% du risque d'événements d'insuffisance cardiaque et une réduction de 56% du risque d'hospitalisation par rapport au placebo. Les patients ont montré une amélioration des symptômes d'insuffisance cardiaque, avec une amélioration de 25 points du score KCCQ-CSS contre 15 points pour le placebo. Les principaux critères secondaires ont révélé que les patients avaient atteint une perte de poids moyenne de 15,7% et ont marché environ 30 mètres de plus en six minutes que le groupe placebo. Le médicament a également réduit le marqueur d'inflammation systémique hsCRP de 43,4%. Lilly a lancé des soumissions réglementaires à l'échelle mondiale.
Eli Lilly hat bedeutende Ergebnisse aus der SUMMIT-Phase-3-Studie zu tirzepatide bei Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF) und Fettleibigkeit bekannt gegeben. Das Medikament zeigte eine 38%ige Reduktion des Risikos von Herzinsuffizienz-Ereignissen und eine 56%ige Reduktion des Risikos von Krankenhausaufenthalten im Vergleich zur Placebogruppe. Die Patienten zeigten eine Verbesserung der Symptome der Herzinsuffizienz, mit einer Verbesserung von 25 Punkten im KCCQ-CSS-Score im Vergleich zu 15 Punkten bei Placebo. Wichtige sekundäre Endpunkte zeigten, dass die Patienten eine Durchschnittliche Gewichtsreduktion von 15,7% erzielten und in sechs Minuten etwa 30 Meter weiter gingen als die Placebogruppe. Das Medikament reduzierte auch den systemischen Entzündungsmarker hsCRP um 43,4%. Lilly hat weltweit regulatorische Einreichungen eingeleitet.
- 38% reduction in heart failure events risk
- 56% reduction in hospitalization risk for heart failure
- 15.7% average body weight reduction vs 2.2% in placebo
- 43.4% decrease in inflammation marker (hsCRP) vs 3.5% in placebo
- Significant improvement in exercise capacity (38.2m vs 7.9m in 6-minute walk test)
- Better symptom improvement (25-point vs 15-point in KCCQ-CSS score)
- Higher treatment discontinuation rate (23 participants vs 5 in placebo)
- Higher cardiovascular death rate in treatment group (2.7% vs 1.4%)
- Significant gastrointestinal side effects (18.4% diarrhea, 17% nausea, 14.8% constipation)
Insights
The SUMMIT Phase 3 trial results for tirzepatide represent a significant breakthrough in treating heart failure with preserved ejection fraction (HFpEF) and obesity. The 38% reduction in heart failure events and 56% reduction in hospitalization risk are clinically meaningful outcomes that could reshape treatment protocols.
The dual impact on both cardiovascular outcomes and weight management is particularly noteworthy, with patients achieving 15.7% weight loss compared to 2.2% in the placebo group. The 43.4% reduction in hsCRP indicates significant anti-inflammatory effects, addressing a key pathophysiological mechanism in HFpEF.
These results could position tirzepatide as a first-in-class therapy for obesity-related HFpEF, potentially creating a new treatment paradigm. With regulatory submissions already initiated, this could translate to substantial market opportunities for Lilly in an underserved therapeutic area.
This data significantly strengthens Lilly's market position in both diabetes and obesity therapeutics. The expansion into heart failure treatment represents a major new revenue opportunity, especially considering there are currently no approved treatments specifically for obesity-related HFpEF in the U.S.
The robust efficacy data and consistent safety profile enhance tirzepatide's commercial potential across multiple indications. With regulatory submissions already underway, approval could lead to substantial market expansion. The addressable market is significant, as HFpEF affects approximately half of all heart failure patients, with obesity being a major contributing factor.
In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations
Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation
Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agencies
Both primary endpoints were met. Tirzepatide showed a
"Many studies point to obesity as a major contributor to the development and severity of heart failure with a preserved ejection fraction through its effects to promote systemic and myocardial inflammation," said Milton Packer, M.D., distinguished scholar in cardiovascular science at Baylor University Medical Center at
All key secondary endpoints were also met, with patients treated with tirzepatide demonstrating improved exercise capacity, walking approximately 30 meters farther in six minutes than those on placebo (38.2 meters vs. 7.9 meters).2 Additionally, patients treated with tirzepatide saw an average reduction in body weight of
Full Results:
Primary Endpoint: Time-to-first occurrence of heart failure outcomes
| ||
Relative risk reduction of time-to-first occurrence of heart failure outcomes (median follow up of 104 weeks):
| - | |
Tirzepatide MTD | Placebo | |
Heart Failure Outcomes* | 36 ( | 56 (15.3 %) |
Cardiovascular death** | 10 (2.7 %) | 5 (1.4 %) |
Adjudicated CV death | 8 (2.2 %) | 5 (1.4 %) |
Undetermined cause | 2 (0.5 %) | 0 |
Heart failure events | 29 (8 %) | 52 (14.2 %) |
Hospitalization for heart failure | 12 (3.3 %) | 26 (7.1 %) |
Urgent visit for heart failure | 5 (1.4 %) | 12 (3.3 %) |
Oral diuretics intensification for heart failure | 17 (4.7 %) | 21 (5.7 %) |
Primary Endpoint: Improvements in heart failure symptoms and physical limitations from baseline as measured by the change from baseline in KCCQ-CSS (points)
| ||
Estimated median difference at 52 weeks | 6.9 | |
Tirzepatide MTD | Placebo | |
Efficacy estimand | 24.8 | 15.0 |
Treatment-regimen estimand | 19.5 | 12.7 |
*Patients can be counted in more than one category listed below. |
**Seven of the 10 people in the tirzepatide group had been off the drug for more than 30 days. |
Key Secondary Endpoints
| |||
Tirzepatide MTD | Placebo | ||
Change in 6-minute walk distance from baseline to 52 weeks (m) | Efficacy estimand | 38.2 | 7.9 |
Treatment-regimen estimand | 26.0 | 10.1 | |
Change in body weight from baseline to 52 weeks (%) | Efficacy estimand | -15.7 | -2.2 |
Treatment-regimen estimand | -13.9 | -2.2 | |
Change in high-sensitivity C-reactive protein from baseline to 52 weeks (%) | Efficacy estimand | -43.4 | -3.5 |
Treatment-regimen estimand | -38.8 | -5.9 | |
"Cardiometabolic diseases, such as heart failure and obesity, are closely linked and often coexist. New approaches are needed to address the interrelated nature of these diseases. At Lilly, we want to better understand the root causes of these conditions and how they impact each other so we're better able to treat them," said Jeff Emmick, M.D., Ph.D., senior vice president, product development, Lilly. "Currently, no treatments are available specifically for obesity-related HFpEF in the
The overall safety profile of tirzepatide in the SUMMIT trial was consistent with previously reported tirzepatide studies. The most frequently reported adverse events were primarily gastrointestinal related and generally mild to moderate in severity. The most common adverse events reported by those on tirzepatide compared with placebo, respectively, were diarrhea (
Additional data from SUMMIT will be presented during AHA and published in peer-reviewed journals. Lilly submitted tirzepatide for the treatment of HFpEF and obesity to the
About SUMMIT
SUMMIT (NCT04847557) was a multi-center, randomized, double-blind, parallel, placebo-controlled Phase 3 study comparing the efficacy and safety of tirzepatide to placebo in adults living with heart failure with preserved ejection fraction (HFpEF) and obesity, with or without type 2 diabetes. The trial randomized 731 participants across the
SUMMIT utilized MTD of 5 mg, 10 mg or 15 mg once weekly. The starting dose of 2.5 mg tirzepatide was increased by 2.5 mg every four weeks until MTD was achieved. Participants who tolerated 15 mg continued on 15 mg as their MTD. Participants who tolerated 10 mg but did not tolerate 15 mg continued on 10 mg as their MTD, and participants who tolerated 5 mg but did not tolerate 10 mg continued on 5 mg as their MTD.
About tirzepatide
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake and the effects are likely mediated by affecting appetite. Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are also ongoing. Lilly submitted data for tirzepatide in moderate-to-severe obstructive sleep apnea (OSA) and obesity to the
Tirzepatide was approved by the
Tirzepatide is the only approved dual GIP and GLP-1 receptor agonist treatment to reduce excess body weight and maintain weight reduction long term. Both Mounjaro and Zepbound should be used in combination with diet and exercise.
ZEPBOUND INDICATION AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems to lose excess body weight and keep the weight off. It should be used with a reduced-calorie diet and increased physical activity.
- Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
- Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
- Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.
Zepbound may cause serious side effects, including:
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration.
Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.
Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.
Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.
Depression or thoughts of suicide. You should pay attention to changes in your mood, behaviors, feelings or thoughts. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.
Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before using Zepbound
- Your healthcare provider should show you how to use Zepbound before you use it for the first time.
- Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them.
- If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound.
Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. It is not known if Zepbound passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.
- Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979).
How to take
- Read the Instructions for Use that come with Zepbound.
- Use Zepbound exactly as your healthcare provider says.
- Use Zepbound with a reduced-calorie diet and increased physical activity.
- Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
- Use Zepbound 1 time each week, at any time of the day.
- Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.
- If you take too much Zepbound, call your healthcare provider, seek medical advice promptly, or contact a Poison Center expert right away at 1-800-222-1222.
Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.
This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.
ZP CON CBS 18OCT2024
Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
MOUNJARO INDICATION AND SAFETY SUMMARY WITH WARNINGS
Mounjaro® (mown-JAHR-OH) is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).
- It is not known if Mounjaro can be used in people who have had inflammation of the pancreas (pancreatitis). Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age.
Warnings - Mounjaro may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
- Do not use Mounjaro if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
- Do not use Mounjaro if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Do not use Mounjaro if you are allergic to it or any of the ingredients in Mounjaro.
Mounjaro may cause serious side effects, including:
Inflammation of the pancreas (pancreatitis). Stop using Mounjaro and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger, weakness and feeling jittery.
Serious allergic reactions. Stop using Mounjaro and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.
Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration.
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Mounjaro. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Mounjaro.
Gallbladder problems. Gallbladder problems have happened in some people who use Mounjaro. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), and clay-colored stools.
Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Mounjaro may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Mounjaro before you are scheduled to have surgery or other procedures.
Common side effects
The most common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Mounjaro. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.
Tell your healthcare provider if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before using Mounjaro
- Your healthcare provider should show you how to use Mounjaro before you use it for the first time.
- Talk to your healthcare provider about low blood sugar and how to manage it.
- If you take birth control pills by mouth, talk to your healthcare provider before you use Mounjaro. Birth control pills may not work as well while using Mounjaro. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Mounjaro and for 4 weeks after each increase in your dose of Mounjaro.
Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take other diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? It is not known if Mounjaro will harm your unborn baby or pass into your breast milk.
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
How to take
- Read the Instructions for Use that come with Mounjaro.
- Use Mounjaro exactly as your healthcare provider says.
- Mounjaro is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
- Use Mounjaro 1 time each week, at any time of the day.
- Do not mix insulin and Mounjaro together in the same injection.
- You may give an injection of Mounjaro and insulin in the same body area (such as your stomach area), but not right next to each other.
- Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.
- If you take too much Mounjaro, call your healthcare provider or seek medical advice promptly.
Learn more
Mounjaro is a prescription medicine available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. For more information, call 1-833-807-MJRO (833-807-6576) or go to www.mounjaro.lilly.com.
This summary provides basic information about Mounjaro but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Mounjaro and how to take it. Your healthcare provider is the best person to help you decide if Mounjaro is right for you.
TR CON CBS 05NOV2024
Mounjaro® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about tirzepatide as a potential treatment for adults with heart failure with preserved ejection fraction (HFpEF) and obesity and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that tirzepatide will prove to be a safe and effective treatment for HFpEF and obesity, that tirzepatide will receive additional regulatory approvals or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
References
- The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) is a patient-reported outcome instrument that uses a 1-100 point scale to assess heart failure symptoms and physical limitations. Higher KCCQ-CSS values indicate better symptom management and reduced physical limitations in people with heart failure.
- For the efficacy estimand, which represents efficacy had all participants continued to receive randomized study medication throughout the study.
Refer to: Kristiane Silva Bello; bello_kristiane@lilly.com; 317-315-9052 (Media)
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/lillys-tirzepatide-reduced-the-risk-of-worsening-heart-failure-events-by-38-in-adults-with-heart-failure-with-preserved-ejection-fraction-hfpef-and-obesity-302307587.html
SOURCE Eli Lilly and Company
FAQ
What were the main results of Lilly's (LLY) SUMMIT trial for tirzepatide?
What side effects were reported for tirzepatide in Lilly's (LLY) SUMMIT trial?
How much did tirzepatide improve exercise capacity in Lilly's (LLY) SUMMIT trial?
